title: Flavoxate treatment of micturition disorders accompanying benign prostatic hypertrophy: a double-blind placebo-controlled multicenter investigation.
abstract: To investigate the effect of flavoxate (Urispadol) treatment on patients with symptomatic benign prostatic hypertrophy (BPH), with the main weight on the irritative symptoms, a randomized, double-blind, parallel-group, placebo-controlled and multicenter investigation was carried out. Seventy patients entered the study, 37 were allocated to flavoxate treatment on a daily dose of 1,200 mg (400 mg t.i.d.) for 12 weeks, and 33 patients were allocated to placebo treatment. In spite of a sufficient power, the study did not discriminate the two treatment groups in a statistically significant way (p > 0.05), when considering the main endpoints: the irritative symptom score and the global patient evaluation. Conservative treatment of micturition disorders accompanying BPH with flavoxate in doses of 1,200 mg/day cannot be recommended for clinical use.
authors.affiliation: Urological Department, Gentofte Hospital, Denmark.
authors.forename: T L
authors.initials: TL
authors.lastname: Dahm
authors.forename: P
authors.initials: P
authors.lastname: Ostri
authors.forename: J K
authors.initials: JK
authors.lastname: Kristensen
authors.forename: S
authors.initials: S
authors.lastname: Walter
authors.forename: C
authors.initials: C
authors.lastname: Frimodt-Møller
authors.forename: R B
authors.initials: RB
authors.lastname: Rasmussen
authors.forename: M
authors.initials: M
authors.lastname: Nøhr
authors.forename: N
authors.initials: N
authors.lastname: Alexander
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D004311:Double-Blind Method; D005422:Flavoxate / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000009:adverse effects / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000150:complications*; D014555:Urination Disorders / Q000188:drug therapy* / Q000209:etiology
chemical_list: D010276:Parasympatholytics; D005422:Flavoxate